In a research note, Edison predicted Epidiolex will generate peak sales of $195m in Dravet syndrome, $601m in Lennox-Gastaut and $255 million in TSC, based on a 2018 launch year.

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis ...